Sana Biotechnology SANA Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's operating lease right-of-use asset amortization?
- Sana Biotechnology (SANA) reported operating lease right-of-use asset amortization of $2.47M in Q1 2026.
- How has Sana Biotechnology's operating lease right-of-use asset amortization changed year-over-year?
- Sana Biotechnology's operating lease right-of-use asset amortization increased by 10.5% year-over-year, from $2.23M to $2.47M.
- What is the long-term trend for Sana Biotechnology's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Sana Biotechnology's operating lease right-of-use asset amortization has grown at a 7.6% compound annual growth rate (CAGR), from $6.84M to $9.17M.